Mirum Pharmaceuticals Future Growth
Future criteria checks 5/6
Mirum Pharmaceuticals is forecast to grow earnings and revenue by 69.5% and 25% per annum respectively. EPS is expected to grow by 70.6% per annum. Return on equity is forecast to be -21.4% in 3 years.
Key information
69.5%
Earnings growth rate
70.6%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | 25.0% |
Future return on equity | -21.4% |
Analyst coverage | Good |
Last updated | 19 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 507 | 43 | 51 | 133 | 6 |
12/31/2025 | 405 | -25 | 7 | 0 | 10 |
12/31/2024 | 313 | -77 | -28 | -6 | 10 |
3/31/2024 | 224 | -159 | -42 | -37 | N/A |
12/31/2023 | 186 | -163 | -91 | -71 | N/A |
9/30/2023 | 145 | -164 | -104 | -74 | N/A |
6/30/2023 | 116 | -176 | -112 | -81 | N/A |
3/31/2023 | 96 | -129 | -115 | -99 | N/A |
12/31/2022 | 77 | -136 | -120 | -120 | N/A |
9/30/2022 | 52 | -42 | -138 | -119 | N/A |
6/30/2022 | 39 | -53 | -146 | -127 | N/A |
3/31/2022 | 32 | -70 | -166 | -147 | N/A |
12/31/2021 | 19 | -84 | -152 | -133 | N/A |
9/30/2021 | 16 | -179 | -136 | -136 | N/A |
6/30/2021 | 11 | -153 | -119 | -119 | N/A |
3/31/2021 | N/A | -132 | -96 | -96 | N/A |
12/31/2020 | N/A | -103 | -89 | -89 | N/A |
9/30/2020 | N/A | -84 | -67 | -66 | N/A |
6/30/2020 | N/A | -78 | -65 | -64 | N/A |
3/31/2020 | N/A | -68 | -56 | -55 | N/A |
12/31/2019 | N/A | -53 | -40 | -39 | N/A |
9/30/2019 | N/A | -61 | -38 | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MIRM * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.8%).
Earnings vs Market: MIRM * is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MIRM * is expected to become profitable in the next 3 years.
Revenue vs Market: MIRM *'s revenue (25% per year) is forecast to grow faster than the MX market (6.9% per year).
High Growth Revenue: MIRM *'s revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MIRM * is forecast to be unprofitable in 3 years.